###### Strengths and limitations of this study

-   This systematic review is, to the best of our knowledge, the first to synthesise evidence on the costs and cost-effectiveness of point-of-care testing and treatment of common and curable sexually transmitted and genital infections in pregnancy in low-income and middle- income countries.

-   This review will assess the completeness of reporting practices and identify areas for improvement in the field.

-   If the interstudy heterogeneity of results may prevent a meta-analysis, we will conduct a narrative synthesis of findings.

-   The review is limited to how studies empirically depict costs and cost-effectiveness.

-   The review is limited to studies published in peer-reviewed journals.

Introduction {#s1}
============

Globally, the growing burden of common curable sexually transmitted and genital infections such as chlamydia, gonorrhoea, syphilis, trichomonas and bacterial vaginosis (henceforth, STIs) is alarming. The majority of infections occur in low-income and middle-income countries (LMICs).[@R1] WHO estimated that in 2012 there were 357.4 million new cases of chlamydia, gonorrhoea, syphilis and trichomonas.[@R2] Left untreated, these STIs can have adverse effects on sexual and reproductive health, neonatal and child health.[@R3] During pregnancy, untreated STIs are associated with an increased risk of adverse pregnancy and birth outcomes, including miscarriage, preterm delivery, stillbirth, low birth weight, neonatal death and neonatal eye and respiratory infections following intrapartum transmission.[@R6]

There is strong evidence to suggest that the detection and treatment of HIV and syphilis early in pregnancy reduces adverse pregnancy and birth outcomes.[@R12] Several studies have indicated that the early detection and treatment of STIs, such as chlamydia, trichomonas and gonorrhoea, in pregnancy could reduce the risk of adverse pregnancy and birth outcomes.[@R16] However, despite high prevalence rates in LMICs few studies in these settings investigate the detection and treatment of common, curable STIs early in pregnancy to prevent adverse outcomes. This is largely because up until recently the accurate detection of these STIs in pregnancy required laboratory-based testing, which is a relatively expensive form of diagnosis in LMICs.[@R18] Other factors include poor infrastructure, limited human resources and high operational costs.[@R19]As a result, clinicians in many LMICs rely on the WHO-endorsed strategy of syndromic management to diagnose and treat symptomatic STIs, which is based on presentation of clinical symptoms and signs without laboratory confirmation.[@R18] This strategy has limited specificity for accurate diagnosis, particularly among pregnant women where asymptomatic infections are common.[@R19]

Advances in STIs detection have played a key role in improving diagnosis and subsequent treatment in LMICs. The widespread adoption of point-of-care (POC) testing for HIV and syphilis, is perhaps a signal of this.[@R23] These tests allow patients to be tested, diagnosed and treated in a single visit to a health facility.[@R24] There is evidence that suggests the introduction of POC tests for HIV and syphilis at antenatal clinics has reduced the rate of perinatal and infant morbidity and mortality in many LMICs.[@R25] This evidence, however, cannot single-handedly drive the implementation of STIs screening programmes. POC testing also presents a particularly challenging scenario. On the one hand, the unit cost-per-test is higher owing to the loss of economies of scale offered by automation, typically by centralised laboratories. On the other hand, it offers the potential of substantial savings through enabling the rapid delivery of results and treatment, avoiding the need for recall and loss of patients requiring treatment, and the associated reduction of facility costs.[@R27] Economic evaluations provide evidence on the relative cost-effectiveness of implementation and can help address these considerations and inform resource allocation. While the number of studies analysing the cost and cost-effectiveness of POC testing and treatment of STIs in pregnancy in LMICs is increasing, there have been no systematic reviews synthesising this body of literature.

The objective of this protocol is to identify, compare, synthesise and appraise the existing evidence on the costs and cost-effectiveness of POC testing and treatment of common, curable STIs (namely, chlamydia, gonorrhoea, syphilis, trichomonas and bacterial vaginosis) in pregnancy in LMICs. The specific objectives of this review are:

1.  Identify and synthesise the evidence on the cost and cost-effectiveness of POC testing and treatment for STIs in pregnancy in LMICs.

2.  Compare and contrast the key findings from existing literature on the cost and cost-effectiveness of POC testing and treatment for STIs in pregnancy in LMICs.

3.  Identify the key drivers of costs and cost-effectiveness of POC testing and treatment for STIs in pregnancy in LMICs.

4.  Appraise the quality of reporting and methodological approaches of using published checklists.

Methods {#s2}
=======

Study type, participants and intervention {#s2-1}
-----------------------------------------

The systematic review will only consider peer-reviewed cost and cost-effectiveness analyses of POC testing and treatment of STIs. We define a POC test as a diagnostic tool that requires only one visit, where the test is conducted and the result is received at the same visit. The test is simple, accurate (both specific and sensitive) and non-invasive, it is user-friendly, compact, durable and sturdy.[@R24] Specifically, the review will include studies that focus on POC testing and treatment of common, curable STIs, namely syphilis, chlamydia, trichomonas gonorrhoea and bacterial vaginosis among pregnant women. Only studies based in LMICs, where the burden of STIs is the greatest will be included. Lastly, the review will include cost and cost-effectiveness analyses conducted within a framework of randomised controlled trials, pilot and feasibility studies and modelling studies.

Exclusion criteria {#s2-2}
------------------

Predetermined exclusion criteria will be applied after the initial literature search. We will only include full peer-reviewed articles and exclude book chapters, commentaries, conference publications/abstracts, editorials, letters, meeting outcomes, recommendations, protocols and reviews. We will also exclude grey literature from the review. Grey literature tends to focus on study conclusions without a rigorous methodological description that could facilitate evaluating study quality. Although another limitation, during the title and abstract screening, we will exclude studies that are not in English. This reflects the language proficiency of the study team. Studies of populations other than pregnant women and on infections other than syphilis, gonorrhoea, chlamydia, trichomonas or bacterial vaginosis will also be excluded. The focus of the studies included must be a POC test for STIs and comparators include, but are not limited to, no screening, syndromic management and existing screening programmes. We will exclude all studies not conducted in LMICs. The LMIC classification is sourced from the World Bank list comprised in 2018.[@R29] We will not apply date and/or time of publication limitations.

Search strategy {#s2-3}
---------------

The literature search for this systematic review will be independently conducted by two reviewers (OPMS and NB). First, OPMS and NB will independently search three preselected electronic databases, MEDLINE, Embase and Web of Science, using keywords and Medical Subject Headings (MeSH) terms, spanning relevant subject matter. The search terms determined by OPMS, NB, LC, AV and VW, in consultation with experienced medical librarians at University College London and the University of New South Wales are presented in a condensed form in [table 1](#T1){ref-type="table"}. The search terms selected reflect relative search sensitivity and specificity, whereby a comprehensive search is balanced with identifying a manageable number of citations. No restrictions will be applied to the literature search. Boolean operators will be included---'OR' within each group of keywords and MeSH terms to indicate the areas of interest, and 'AND' to combine each group and find articles related to the main objective of the systematic review. Lastly, terms will be exploded and truncated where necessary.

###### 

Proposed keywords and MeSH terms for the literature search

  Themes                                        Proposed keywords and MeSH terms
  --------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  Economic evaluations                          Cost-effectiveness OR cost benefit analysis (MeSH term) OR cost analysis
  Sexually transmitted and genital infections   Sexually transmitted infections OR Sexually transmitted Diseases OR Gonorrhoea OR Chlamydia OR Trichomonas OR Syphilis OR Bacterial Vaginosis
  Point-of-care testing                         Point-of-care testing (MeSH term) OR point-of-care OR rapid OR bedside OR near-to-patient OR test OR lateral flow OR screening
  Pregnancy                                     Pregnancy OR pregnant women OR ANC OR antenatal

MeSH, Medical Subject Headings.

OPMS and NB will then independently search for literature using Google Scholar. The first 100 results will be screened to identify additional literature, which may capture articles missed by the database searches. Finally, OPMS and NB will each conduct a hand search of references included in the final set of articles.

Data extraction and analysis {#s2-4}
----------------------------

All citations found through the literature search will be exported into Endnote X8 (Thomson Reuters) and duplicates will be removed. OPMS and NB will independently screen all titles, keywords and abstracts to collate a set of articles for full-text review based on the inclusion and exclusion criteria. OPMS and NB will then independently review the full texts of selected studies and apply the inclusion and exclusion criteria to compile the final set of studies to be included in the review. In the case of disputes, VW will make the final decision to include or exclude studies. Literature included in this review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The screening process, illustrated in [figure 1](#F1){ref-type="fig"}, shows the proposed PRISMA flow diagram for this review.

![PreferredReporting Items for Systematic Reviews and Meta-Analyses flow diagram of the search selection for this systematic review.](bmjopen-2019-029945f01){#F1}

Data will be extracted into Microsoft Excel 2013 and will include details on the authors, title, type of intervention, comparator, study setting, study design, perspective adopted, time horizon and key cost and cost-effectiveness indicators results of each study. The Drummond checklist will be used in this systematic review to assess the methodological quality of the included studies[@R30] in conjunction with the novel Consolidated Health Economic Evaluation Reporting Standards checklist[@R31] to assess the consistency and transparency of reporting. The Drummond 10-item, 13-criteria checklist[@R30] is a simplified version of the more detailed 35-item Drummond version, providing comprehensive guidance on the methodological conduct of an economic evaluation. It is recommended in the Cochrane Handbook for Systematic Reviews of Interventions.[@R32] The appraisal will be independently undertaken by OPMS and NB and in case of disputes, VW will arbitrate. Careful consideration will also be given to publication bias across studies and selective reporting within studies.

Data extracted for the analysis will include primary outcomes or end points, such as total cost of the intervention, unit costs, cost-effectiveness and incremental cost-effectiveness ratios (such as cost per outcome and cost per disability-adjusted life years averted), cost savings to the health system, budget impact estimates. We will also extract data on context-related factors, such as factors included in sensitivity analyses that could affect the costs and cost-effectiveness of interventions. This will allow us to explore a wide range of intervention programmes, economic evaluation methods, costs and outcomes and to identify and discuss the variation in drivers of costs and cost-effectiveness. A high degree of heterogeneity in the primary studies is anticipated---including differences in cost-effectiveness outcomes, study designs and health interventions and comparators---which will limit our ability to conduct a meta-analysis. If methodological heterogeneity is confirmed then a descriptive summary and narrative synthesis will be undertaken. Furthermore, if a subset of studies have comparable cost-effectiveness outcomes, and the sample is large enough to do a rigorous meta-analysis this will be conducted using Stata IC V.14.0 (StataCorp, College Station, Texas, USA).

Study dates {#s2-5}
-----------

This study is ongoing; the anticipated date of completion is 31 December 2019.

Patient and public involvement {#s3}
==============================

Patients and/or the public were not directly involved in the development of this systematic review protocol.

Ethics and dissemination {#s4}
========================

The results of this review will be published in a peer-reviewed, open access journal and presented an international conference.

Discussion {#s5}
==========

Common, curable STIs in pregnancy have multiple adverse effects and left untreated can be harmful to both mothers and babies. LMICs have the highest burden of STIs, highlighting the need for affordable and cost-effective screening interventions in these settings. Collating current evidence on costs and cost-effectiveness of POC testing and treatment of STIs in pregnancy is an important first step in understanding the value of these tests in highly resource-constrained health systems. It also provides an opportunity to gauge the quality of reporting conventions used in the different studies. To our knowledge, this represents the first systematic review on this topic.
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